Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Personnel related research and development expenses Personnel Related Research And Development Expense Personnel Related Research And Development Expense Segment Reporting [Abstract] Schedule of Restricted Stock Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Accrued compensation Employee-related Liabilities, Current Restatement Determination Date Restatement Determination Date Schedule Of Cost Sharing Payments And Reimbursements Schedule Of Cost Sharing Payments And Reimbursements [Table Text Block] Schedule Of Cost Sharing Payments And Reimbursements Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Proceeds from divestiture Proceeds from Divestiture of Businesses Number of securities called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Options, vested and expected to vest (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Project [Axis] Project [Axis] Initial investment proceeds multiple, maximum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Maximum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Maximum Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Payments for finance lease right-of-use asset Finance Lease, Principal Payments Proceeds from sale of revenue participation right Proceeds From Sale Of Revenue Participation Right Liability Related to the Revenue Participation Right Agreement Class of Warrant or Right [Table] Class of Warrant or Right [Table] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Unrealized Holding Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Collaborative agreement, aggregate consideration amount Collaborative Agreement, Aggregate Consideration Amount Collaborative Agreement, Aggregate Consideration Amount Transaction costs Royalty Funding Arrangement, Transaction Costs Royalty Funding Arrangement, Transaction Costs Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Liability Related to the Revenue Participation Right Royalty Funding Arrangement [Text Block] Royalty Funding Arrangement PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Assets: Assets, Fair Value Disclosure [Abstract] Intangible asset, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accruals and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Weighted average number of shares outstanding, basic (in shares) Weighted average number of shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited [Member] Takeda pharmaceutical company limited. Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Loss before income taxes Income (Loss) Attributable to Parent, before Tax Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Collaborative Arrangement, PTV:PGRN Collaborative Arrangement, PTV:PGRN [Member] Collaborative Arrangement, PTV:PGRN Work in process Inventory, Work in Process, Net of Reserves Interest and other income, net Segment interest and other income, net Interest and Other Income Entity Address, City or Town Entity Address, City or Town Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Finance lease cost: Finance Lease, Cost [Abstract] Finance Lease, Cost Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Class of Stock [Axis] Class of Stock [Axis] Vested and released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Product Product [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Intangible assets, finite-lived, net Total Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Payments for royalties Payments for Royalties Intangible asset accumulated amortization Intangible Asset, Finite-Lived, Accumulated Amortization Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] AVLAYAH AVLAYAH [Member] AVLAYAH Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Contingent payments upon achievement of milestones Contingent Payments Upon Achievement Of Milestones Contingent Payments Upon Achievement Of Milestones Number of new contracts Collaborative Arrangement, Number Of New Contracts Collaborative Arrangement, Number Of New Contracts Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Schedule of Reconciliation of Segment Loss Before Income Taxes and Total Consolidated Loss Before Income Taxes Segment Reporting [Table Text Block] Common stock shares outstanding (in shares) Weighted Average Number of Shares Issued, Basic Use of Estimates Use of Estimates, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuances under equity incentive plans (in shares) Stock Issued During Period, Shares, Equity Incentive Plan Stock Issued During Period, Shares, Equity Incentive Plan Peripheral Program License Peripheral Product [Member] Peripheral Product Accrued clinical and other research & development costs Accrued Clinical And Other Accrued Research And Development Costs Accrued Clinical And Other Accrued Research And Development Costs Expected to vest (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Date Fair Value Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Convertible preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common Stock Equity [Text Block] Security Exchange Name Security Exchange Name Deferred research and development funding liability Increase (Decrease) In Deferred Liability, Capitalized Research and Development Costs Increase (Decrease) In Deferred Liability, Capitalized Research and Development Costs Granted (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Additional payment Royalty Funding Arrangement, Additional Payment Royalty Funding Arrangement, Additional Payment Purchases of marketable securities Payments to Acquire Marketable Securities Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Franchisor Disclosure [Line Items] Franchisor Disclosure [Line Items] Operating lease liability, current Operating Lease, Liability, Current Finance lease right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Maturities and sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Equity securities without readily determinable fair value, impairment loss Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Liability related to the revenue participation right agreement Royalty Funding Arrangement Liability, Noncurrent Royalty Funding Arrangement Liability, Noncurrent Asset acquisition, milestone payment Asset Acquisition, Milestone Payment Asset Acquisition, Milestone Payment Liability Related to the Revenue Participation Right Debt, Policy [Policy Text Block] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted average number of shares outstanding, diluted (in shares) Weighted average number of shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PRV Transfer Agreement PRV Transfer Agreement [Member] PRV Transfer Agreement Disposal Group Name [Domain] Disposal Group Name [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] U.S. government treasuries US Treasury Securities [Member] Net cost sharing payments (reimbursements) Research And Development Expense, Offset From Cost Reimbursement Research And Development Expense, Offset From Cost Reimbursement Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Operating leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Intangible Asset, Goodwill and Other [Abstract] Project [Domain] Project [Domain] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Collaboration And Development Funding Agreement Collaboration And Development Funding Agreement [Member] Collaboration And Development Funding Agreement Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Royalty Pharma Royalty Pharma [Member] Royalty Pharma Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Milestone Triggered Milestone Triggered [Member] Milestone Triggered Pre-funded warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Convertible preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Initial investment proceeds multiple, minimum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Minimum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Minimum Number of RSU shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Deferred research and development funding liability, current Deferred Research And Development Funding Liability, Current Deferred Research And Development Funding Liability, Current Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Segment Information Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Schedule of Future Annual Amortization Expense Intangible Asset, Finite-Lived, Amortization Expense [Table Text Block] Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Asset acquisition, contingent consideration, liability, current Asset Acquisition, Contingent Consideration, Liability, Current Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Options, exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Common stock issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from underwriter exercising option to purchase common stock, net of issuance costs Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Number of common stock sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Exercise Price Award Exercise Price Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Receivable Accounts Receivable, after Allowance for Credit Loss Disposal Group Classification [Domain] Disposal Group Classification [Domain] Authorized funding Royalty Funding Arrangement, Authorized Funding Royalty Funding Arrangement, Authorized Funding Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] External research and development expenses - TV programs, including cost sharing External Research And Development Expense External Research And Development Expense Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Net proceeds Sale of Stock, Consideration Received on Transaction Total operating expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Inventory Inventory, Policy [Policy Text Block] Gross proceeds Disposal Group, Including Discontinued Operation, Consideration Counterparty Name [Domain] Counterparty Name [Domain] Text Block [Abstract] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount LRRK2 Product LRRK2 Product [Member] LRRK2 Product Accrued manufacturing costs Accrued Manufacturing Costs Accrued Manufacturing Costs Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Insider Trading Policies and Procedures [Line Items] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general and administrative Total selling, general and administrative expenses Selling, General and Administrative Expense Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Takeda Collaboration Agreement Takeda Collaboration Agreement [Member] Takeda Collaboration Agreement Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of operating segments Number of Operating Segments Potentially dilutive securities not include in the diluted per share calculations (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Entity Central Index Key Entity Central Index Key Net accretion of discounts on marketable securities Investment Income, Amortization of Discount Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 159,755,526 shares and 156,182,177 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Outstanding All Adjustments to Compensation All Adjustments to Compensation [Member] Reduction to research and development expense Reduction To Research And Development Expense Reduction To Research And Development Expense Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Income Statement [Abstract] Stockholders' equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Biogen Biogen [Member] Biogen Operating expenses: Less: Operating Expenses [Abstract] Finance lease liability, less current portion Finance Lease, Liability, Noncurrent Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Assumptions Used for Estimating the Fair Value of Stock Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Personnel related selling, general and administrative expenses Personnel Related Selling, General And Administrative Expense Personnel Related Selling, General And Administrative Expense Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] City Area Code City Area Code Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Subsequent Event Subsequent Events [Text Block] Collaborative Arrangement Collaborative Arrangement [Member] Deferred research and development funding liability, current Deferred Liability, Capitalized Research And Development Costs, Current Deferred Liability, Capitalized Research And Development Costs, Current Name Forgone Recovery, Individual Name Finished goods Inventory, Finished Goods, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-Average Fair Value at Date of Grant per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Intangible Assets Intangible Asset [Text Block] Statement [Line Items] Statement [Line Items] Long-term marketable securities Marketable Securities, Noncurrent Total assets Assets Milestone payments upon achievement of certain clinical, regulatory and sales milestone events Aggregate Clinical Regulatory And Sales Milestone Payment Aggregate Clinical Regulatory And Sales Milestone Payment Convertible preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Net unrealized loss on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Fair value of investment Equity Securities without Readily Determinable Fair Value, Amount Unrealized Holding Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-Based Awards Share-Based Payment Arrangement [Text Block] Issuance of common stock, net of issuance cost (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Expired (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total Share-Based Payment Arrangement, Expense Short-term marketable securities Marketable Securities, Current Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Domain] Subsequent Event Type [Domain] Milestone Payment Milestone Payment [Member] Milestone Payment Accumulated Deficit Retained Earnings [Member] Operating lease liability, less current portion Operating Lease, Liability, Noncurrent Money market funds Money Market Funds [Member] Series A Preferred Stock Series A Preferred Stock [Member] Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Corporate debt securities Corporate Debt Securities [Member] Net loss per share, diluted (usd per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Total Shareholder Return Amount Total Shareholder Return Amount Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Intangible asset amortization Intangible Asset, Finite-Lived, Amortization Expense Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 Preferred Stock, Value, Outstanding Intangible Asset, Finite-Lived [Line Items] Intangible Asset, Finite-Lived [Line Items] Research and development Research and development expense due to cost share payments to related party Total research and development expenses Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Total revenue Total collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Effective maturity (less than) Debt Securities, Available-for-Sale, Term Financial Instruments [Domain] Financial Instruments [Domain] Collaborative Arrangement, ATV:TREM2 Collaborative Arrangement, ATV:TREM2 [Member] Collaborative Arrangement, ATV:TREM2 Other comprehensive loss: Other Comprehensive Income (Loss), Tax [Abstract] Aggregate payments Collaborative Arrangement, Aggregate Payments Collaborative Arrangement, Aggregate Payments Inventory Inventory Disclosure [Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Issuance of common stock, net of issuance cost Stock Issued During Period, Value, New Issues Over-Allotment Option Over-Allotment Option [Member] Forfeited (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Proceeds from exercise of awards under equity incentive plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Options, exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Inventory Increase (Decrease) in Inventories Non-cash adjustment to operating lease expense Increase (Decrease) In Non-Cash Operating Lease Expense Increase (Decrease) In Non-Cash Operating Lease Expense Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Segment Reporting [Table] Segment Reporting [Table] Biogen Collaborative Arrangement Biogen Collaborative Arrangement [Member] Biogen Collaborative Arrangement Equity Method Investment [Table] Equity Method Investment [Table] Sale of Stock [Axis] Sale of Stock [Axis] Investing activities Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract] Schedule of Lease Costs and Supplemental Information for Lease Amounts Recognized Lease, Cost [Table Text Block] Schedule of Available for Sale Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Operating activities Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Regulatory Regulatory [Member] Regulatory Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Current Fiscal Year End Date Current Fiscal Year End Date Gain on disposition Gain (Loss) on Disposition of Business Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Short-term marketable securities: Debt Securities, Available-for-Sale, Current Equity Components [Axis] Equity Components [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Entity Interactive Data Current Entity Interactive Data Current Finance lease liability, current Finance Lease, Liability, Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Subsequent Events [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other non-current assets Other Assets, Noncurrent Financing activities Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract] Document Type Document Type Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Other accrued costs and current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment, Excluding Long-Term Commitment [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Significant Accounting Policies Significant Accounting Policies [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Supply of Commercial Product Supply of Commercial Product [Member] Supply of Commercial Product Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Proceeds received Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number Franchisor, Ownership [Table] Franchisor, Ownership [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 10) Commitments and Contingencies Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Right-of-use asset amortization for finance lease Amortization of ROU assets Finance Lease, Right-of-Use Asset, Amortization Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Other Commitments [Table] Other Commitments [Table] Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Inventory Total inventory Inventory, Net Equity Award [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Interest Finance Lease, Interest Expense Shares of pre-funded warrants (in shares) Class of Warrant or Right, Outstanding Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Other selling, general and administrative expenses Other Selling, General and Administrative Expense Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One PEO Name PEO Name Commercial Commercial [Member] Commercial Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Therapeutics Segment Therapeutics Segment [Member] Therapeutics Segment Contract liability Contract with Customer, Liability Royalty rate Royalty Funding Arrangement, Royalty Rate Royalty Funding Arrangement, Royalty Rate Off-balance sheet concentrations of credit risk Concentration Risk, Credit Risk, Financial Instruments, Off-Balance Sheet Risk, Amount Concentration Risk, Credit Risk, Financial Instruments, Off-Balance Sheet Risk, Amount Concentration of Credit Risk and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Long-term marketable securities: Debt Securities, Available-for-Sale, Noncurrent Other Commitments [Line Items] Other Commitments [Line Items] Exercised (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable Increase (Decrease) in Accounts Payable Other accrued costs and current liabilities Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Nancy Thornberry [Member] Nancy Thornberry Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Asset Acquisition, Contingent Consideration, Type [Domain] Asset Acquisition, Contingent Consideration, Type [Domain] Asset Acquisition, Contingent Consideration, Type [Domain] Stock–based compensation expense Share-Based Payment Arrangement, Noncash Expense 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Total lease costs Lease, Cost Disposal Group Name [Axis] Disposal Group Name [Axis] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Net loss per share, basic (usd per share) Earnings Per Share, Basic Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Organization and Description of Business Organization and Description of Business, Policy [Policy Text Block] Organization and description of business, policy. Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Aggregate Fair Value Debt Securities, Available-for-Sale Operating lease cost Operating Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Payment due on intangible asset acquired Noncash or Part Noncash Acquisition, Intangible Assets Acquired Public Offering Public Offering [Member] Public Offering Accounts Receivable Receivable [Policy Text Block] Equity Awards Adjustments Equity Awards Adjustments [Member] Research and Development Funding Collaboration Agreement Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Variable lease cost Variable Lease, Cost Stock Options Options Issued and Outstanding and ESPP Shares Issuable and Outstanding Share-Based Payment Arrangement, Option [Member] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Issuances under equity incentive plans Stock Issued During Period, Value, Equity Incentive Plan Stock Issued During Period, Value, Equity Incentive Plan Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] Restricted cash Restricted Cash and Cash Equivalent, Noncurrent Additional paid-in capital Additional Paid in Capital Annual interest rate Royalty Funding Arrangement, Interest Rate, Effective Percentage Royalty Funding Arrangement, Interest Rate, Effective Percentage Cash paid to acquire finite-lived intangible asset Payments to Acquire Intangible Assets 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Schedule of Accrued Expenses and Other Current Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] 2026 (six months) Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Convertible preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Adjustment to Compensation: Adjustment to Compensation [Axis] Cost of Goods Sold Cost of Goods and Service [Policy Text Block] Non-cash interest expense related to revenue participation right liability Royalty Funding Arrangement, Noncash Interest Expense Royalty Funding Arrangement, Noncash Interest Expense Class of Stock [Domain] Class of Stock [Domain] Non-Marketable Equity Investment Investment in Debt and Equity Instruments and Cash and Cash Equivalent [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Thereafter Intangible Asset, Finite-Lived, Estimated Amortization Expense, after Year Four Intangible Asset, Finite-Lived, Estimated Amortization Expense, after Year Four Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total Assets, Fair Value Disclosure Investments Investment, Policy [Policy Text Block] Options, vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Name Measure Name Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Other non-cash items Other Noncash Income (Expense) Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Collaborative arrangement, cumulative aggregate payments Collaborative Arrangement, Cumulative Aggregate Payments Collaborative Arrangement, Cumulative Aggregate Payments Asset Acquisition, Contingent Consideration, Type [Axis] Asset Acquisition, Contingent Consideration, Type [Axis] Asset Acquisition, Contingent Consideration, Type Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Raw materials Inventory, Raw Materials, Net of Reserves Sanofi Sanofi [Member] Sanofi [Member] Company Selected Measure Amount Company Selected Measure Amount Investments, Debt and Equity Securities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Royalty Agreement Royalty Agreement [Member] Royalty Agreement Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma [Member] Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma Entity Address, Address Line One Entity Address, Address Line One Vested and released (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Cost of goods sold Cost of Product and Service Sold Purchase commitments Purchase Obligation Award Timing Method Award Timing Method [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Other research and development expenses, including small molecule programs Other Research and Development Expense Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Net loss Net loss Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Balance Sheet Location [Axis] Location, Statement of Financial Position, Balance [Axis] Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement, PTV:PGRN and ATV:TREM2 Collaborative Arrangement, PTV:PGRN And ATV:TREM2 [Member] Collaborative Arrangement, PTV:PGRN And ATV:TREM2 Tenvie Therapeutics, Inc Tenvie Therapeutics, Inc [Member] Tenvie Therapeutics, Inc Leases Lessee, Leases [Policy Text Block] Option Fee Payment Option Fee Payment [Member] Option Fee Payment Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Revenue: Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]